Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | DBH | P09172 | 1/20 | 0.39 |
| ▸ | VRK1 | Q99986 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391029 | 0.78 | CES2 (0.36) | TRPA1ALDH1A1TSHR | |
| SCHEMBL14421368 | 0.78 | PTGS1 (0.45) | MEP1BDBHESR1ESR2 | |
| SCHEMBL14234185 | 0.78 | SELL (0.41) | TRPA1ALDH1A1TSHRHTT | |
| SCHEMBL36980 | 0.78 | MEP1B (0.44) | MEP1BDBHESR1ESR2ERN1 | |
| SCHEMBL24357673 | 0.76 | KDM1A (0.37) | MEP1BTRPA1ALDH1A1TSHR | |
| SCHEMBL2642238 | 0.76 | ACHE (0.50) | MEP1BDBHESR1ESR2ERN1 | |
| SCHEMBL4547659 | 0.74 | HDAC1 (0.35) | TRPA1ALDH1A1TSHR | |
| SCHEMBL6124950 | 0.74 | MEP1B (0.41) | MEP1BDBHVRK1TRPA1ALDH1A1 | |
| SCHEMBL25219828 | 0.74 | TRPA1 (0.32) | TRPA1ALDH1A1TSHR | |
| SCHEMBL6302839 | 0.74 | MEP1B (0.41) | MEP1BDBH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977261-B2 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-6974822-B2 | 3-isoquinolinone derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1539709-A1 | AZAISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014866-A1 | AZAISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014378-A1 | 3-ISOQUINOLINONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | MMP1, MMP9, MMP3 | MEP1B 2559/4885DBH 2263/4885VRK1 3679/4885 |
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP1 | MEP1B 889/4885DBH 1806/4885VRK1 4240/4885 |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | MEP1B 2406/4885DBH 1206/4885VRK1 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.